These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Feeney GF; Connor JP; Young RM; Tucker J; McPherson A Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406 [TBL] [Abstract][Full Text] [Related]
25. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Baros AM; Latham PK; Anton RF Alcohol Clin Exp Res; 2008 May; 32(5):771-6. PubMed ID: 18336635 [TBL] [Abstract][Full Text] [Related]
26. Does family history of alcoholism moderate naltrexone's effects on alcohol use? Capone C; Kahler CW; Swift RM; O'Malley SS J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720 [TBL] [Abstract][Full Text] [Related]
27. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers. Schmidt LG; Smolka MN Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634 [TBL] [Abstract][Full Text] [Related]
28. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Anton RF; Moak DH; Waid LR; Latham PK; Malcolm RJ; Dias JK Am J Psychiatry; 1999 Nov; 156(11):1758-64. PubMed ID: 10553740 [TBL] [Abstract][Full Text] [Related]
29. Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. Greenfield SF; Shields A; Connery HS; Livchits V; Yanov SA; Lastimoso CS; Strelis AK; Mishustin SP; Fitzmaurice G; Mathew TA; Shin S Alcohol Clin Exp Res; 2010 Feb; 34(2):317-30. PubMed ID: 19930235 [TBL] [Abstract][Full Text] [Related]
30. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Haber PS; Riordan BC; Winter DT; Barrett L; Saunders J; Hides L; Gullo M; Manning V; Day CA; Bonomo Y; Burns L; Assan R; Curry K; Mooney-Somers J; Demirkol A; Monds L; McDonough M; Baillie AJ; Clark P; Ritter A; Quinn C; Cunningham J; Lintzeris N; Rombouts S; Savic M; Norman A; Reid S; Hutchinson D; Zheng C; Iese Y; Black N; Draper B; Ridley N; Gowing L; Stapinski L; Taye B; Lancaster K; Stjepanović D; Kay-Lambkin F; Jamshidi N; Lubman D; Pastor A; White N; Wilson S; Jaworski AL; Memedovic S; Logge W; Mills K; Seear K; Freeburn B; Lea T; Withall A; Marel C; Boffa J; Roxburgh A; Purcell-Khodr G; Doyle M; Conigrave K; Teesson M; Butler K; Connor J; Morley KC Med J Aust; 2021 Oct; 215 Suppl 7():S3-S32. PubMed ID: 34601742 [TBL] [Abstract][Full Text] [Related]
31. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. Falk DE; Litten RZ; Anton RF; Kranzler HR; Johnson BA; J Stud Alcohol Drugs; 2014 Mar; 75(2):335-46. PubMed ID: 24650828 [TBL] [Abstract][Full Text] [Related]
32. Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Ray LA; Oslin DW Drug Alcohol Depend; 2009 Dec; 105(3):256-8. PubMed ID: 19717248 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacological features of naltrexone and its use in the treatment of alcohol dependence]. Bieńkowski P Psychiatr Pol; 2013; 47(1):117-26. PubMed ID: 23888749 [TBL] [Abstract][Full Text] [Related]
35. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland. Buri C; Moggi F; Giovanoli A; Strik W Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820 [TBL] [Abstract][Full Text] [Related]
36. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. Johnson BA; Ait-Daoud N; Roache JD J Stud Alcohol Suppl; 2005 Jul; (15):157-67; discussion 140. PubMed ID: 16223067 [TBL] [Abstract][Full Text] [Related]
37. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Baser O; Chalk M; Rawson R; Gastfriend DR Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological treatment of alcohol dependence: a review of the evidence. Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148 [TBL] [Abstract][Full Text] [Related]
39. Recent Developments in Pharmacotherapy of Alcoholism. Soyka M; Lieb M Pharmacopsychiatry; 2015 Jul; 48(4-5):123-35. PubMed ID: 25761458 [TBL] [Abstract][Full Text] [Related]
40. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Harris AHS; Ellerbe L; Reeder RN; Bowe T; Gordon AJ; Hagedorn H; Oliva E; Lembke A; Kivlahan D; Trafton JA Psychol Serv; 2013 Nov; 10(4):410-419. PubMed ID: 23356858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]